Omacor for Perimenopausal Depression
|ClinicalTrials.gov Identifier: NCT00517972|
Recruitment Status : Withdrawn
First Posted : August 17, 2007
Last Update Posted : March 29, 2012
|Condition or disease||Intervention/treatment||Phase|
|Depression||Drug: Omacor (omega-3-acid ethyl esters)||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Omacor for Perimenopausal Depression|
- Reduction of the initial HAM-D score by 50% or more at week 8 of the trial.
- Reduction of the HAM-D score to less than 7 at week 8.
- Clinical Global Impression change in score achievement to "very much improved" or "much improved" at week 8.
- Decrease in the Greene Climacteric Scale by 50%.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00517972
|United States, Arizona|
|Women's Mental Health Program; University of Arizona|
|Tucson, Arizona, United States, 85724|
|Principal Investigator:||Marlene P Freeman, M.D.||University of Arizona|